Syon Capital LLC Increases Position in Kenvue Inc. (NYSE:KVUE)

Syon Capital LLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 78.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,276 shares of the company’s stock after purchasing an additional 12,865 shares during the period. Syon Capital LLC’s holdings in Kenvue were worth $630,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of KVUE. CWM LLC boosted its position in shares of Kenvue by 1,521.1% during the third quarter. CWM LLC now owns 12,969 shares of the company’s stock worth $260,000 after acquiring an additional 12,169 shares during the last quarter. AE Wealth Management LLC bought a new position in shares of Kenvue during the third quarter worth $619,000. IFP Advisors Inc bought a new position in shares of Kenvue during the third quarter worth $38,000. Global Retirement Partners LLC bought a new position in shares of Kenvue during the third quarter worth $28,000. Finally, SG Americas Securities LLC bought a new position in shares of Kenvue during the third quarter worth $1,062,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on KVUE. Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. William Blair began coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating for the company. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Finally, Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Trading Down 0.8 %

NYSE KVUE traded down $0.16 during trading on Friday, reaching $18.86. 15,451,236 shares of the company’s stock traded hands, compared to its average volume of 16,691,828. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The company’s 50 day simple moving average is $19.84 and its two-hundred day simple moving average is $20.14. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The business’s revenue was down 2.7% on a year-over-year basis. Research analysts anticipate that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.24%. The ex-dividend date is Tuesday, May 7th.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.